Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
People with NAFLD have an elevated risk of cancer, largely due to high liver cancer incidence.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Weight-loss surgery especially reduced obesity-related cancers in people with liver cirrhosis.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
Mice that performed modest exercise were less likely to show signs of inflammation, cell aging and liver cancer.
Blue Faery’s “Love Your Liver” 28-day video campaign raises awareness of liver cancer and overall liver health.
Compared to other racial and ethnic groups, Blacks are also less likely to be diagnosed early.
Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.
This measurement also informed researchers about the risk of loss of liver function and death in people cured of hepatitis C.
Areas with lower population density have not seen the same slowdown as urban areas.
Almost one in six people with cirrhosis have moderate to severe depression, and close to half have moderate to severe anxiety.
Culturally mindful educational programs may help Black people seek help earlier and throttle hep B incidence rates in these communities.
Women also had a higher rate of hepatocellular carcinoma in the absence of cirrhosis.
No significant links were found between liver stiffness prior to antiviral treatment and cirrhosis, liver cancer or transplants or death.
Readily available clinical parameters can identify those at greatest risk for hepatocellular carcinoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.